FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168664391> ?p ?o ?g. }

• W2168664391 endingPage "2051" @default.
• W2168664391 startingPage "2044" @default.
• W2168664391 abstract "Purpose This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in patients with untreated extensive-disease small-cell lung cancer (ED-SCLC). Patients and Methods A total of 784 patients were randomly assigned to either oral topotecan 1.7 mg/m 2 /d × 5 with IV cisplatin 60 mg/m 2 on day 5 (n = 389) or IV etoposide 100 mg/m 2 /d × 3 with IV cisplatin 80 mg/m 2 on day 1 (n = 395) every 21 days. Results Overall survival (primary end point) was similar between groups (P = .48; median: TC, 39.3 weeks v PE, 40.3 weeks). One-year survival was 31% (95% CI, 27% to 36%) in both groups and the difference of −0.03 (95% CI, −6.53 to 6.47) met the predefined criteria of ≤ 10% absolute difference for noninferiority of TC relative to PE. Response rates were similar between groups (TC, 63% v PE, 69%). Time to progression was slightly but statistically longer with PE (log-rank P = .02; median: TC, 24.1 weeks v PE, 25.1 weeks). The regimens were similarly tolerable. Grade 3/4 neutropenia occurred more frequently with PE (84% v 59%), whereas grade 3/4 anemia and thrombocytopenia occurred more frequently with TC (38% v 21% and 38% v 23%, respectively). Lung Cancer Symptom Scale scores were statistically better with PE, but the differences were small and of debatable clinical significance. Conclusion Oral topotecan with cisplatin provides similar efficacy and tolerability to the standard (etoposide with cisplatin) in untreated ED-SCLC and may provide greater patient convenience compared with intravenous etoposide and cisplatin." @default.
• W2168664391 created "2016-06-24" @default.
• W2168664391 creator A5009049651 @default.
• W2168664391 creator A5011641592 @default.
• W2168664391 creator A5026119562 @default.
• W2168664391 creator A5033749771 @default.
• W2168664391 creator A5052662493 @default.
• W2168664391 creator A5065002137 @default.
• W2168664391 creator A5069473904 @default.
• W2168664391 creator A5071938679 @default.
• W2168664391 creator A5075651605 @default.
• W2168664391 date "2006-05-01" @default.
• W2168664391 modified "2023-10-10" @default.
• W2168664391 title "Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer" @default.
• W2168664391 cites W1859729923 @default.
• W2168664391 cites W1932169383 @default.
• W2168664391 cites W2023626223 @default.
• W2168664391 cites W2033419025 @default.
• W2168664391 cites W2049081179 @default.
• W2168664391 cites W2060723768 @default.
• W2168664391 cites W2071102043 @default.
• W2168664391 cites W2094615395 @default.
• W2168664391 cites W2099333512 @default.
• W2168664391 cites W2099756452 @default.
• W2168664391 cites W2123767004 @default.
• W2168664391 cites W2136994222 @default.
• W2168664391 cites W2147635576 @default.
• W2168664391 cites W2150878803 @default.
• W2168664391 cites W2155243531 @default.
• W2168664391 cites W2168227366 @default.
• W2168664391 doi "https://doi.org/10.1200/jco.2005.03.3332" @default.
• W2168664391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16648504" @default.
• W2168664391 hasPublicationYear "2006" @default.
• W2168664391 type Work @default.
• W2168664391 sameAs 2168664391 @default.
• W2168664391 citedByCount "131" @default.
• W2168664391 countsByYear W21686643912012 @default.
• W2168664391 countsByYear W21686643912013 @default.
• W2168664391 countsByYear W21686643912014 @default.
• W2168664391 countsByYear W21686643912015 @default.
• W2168664391 countsByYear W21686643912016 @default.
• W2168664391 countsByYear W21686643912017 @default.
• W2168664391 countsByYear W21686643912018 @default.
• W2168664391 countsByYear W21686643912019 @default.
• W2168664391 countsByYear W21686643912020 @default.
• W2168664391 countsByYear W21686643912021 @default.
• W2168664391 countsByYear W21686643912022 @default.
• W2168664391 countsByYear W21686643912023 @default.
• W2168664391 crossrefType "journal-article" @default.
• W2168664391 hasAuthorship W2168664391A5009049651 @default.
• W2168664391 hasAuthorship W2168664391A5011641592 @default.
• W2168664391 hasAuthorship W2168664391A5026119562 @default.
• W2168664391 hasAuthorship W2168664391A5033749771 @default.
• W2168664391 hasAuthorship W2168664391A5052662493 @default.
• W2168664391 hasAuthorship W2168664391A5065002137 @default.
• W2168664391 hasAuthorship W2168664391A5069473904 @default.
• W2168664391 hasAuthorship W2168664391A5071938679 @default.
• W2168664391 hasAuthorship W2168664391A5075651605 @default.
• W2168664391 hasBestOaLocation W21686643911 @default.
• W2168664391 hasConcept C126322002 @default.
• W2168664391 hasConcept C141071460 @default.
• W2168664391 hasConcept C197934379 @default.
• W2168664391 hasConcept C2776256026 @default.
• W2168664391 hasConcept C2776694085 @default.
• W2168664391 hasConcept C2777063308 @default.
• W2168664391 hasConcept C2778119113 @default.
• W2168664391 hasConcept C2778239845 @default.
• W2168664391 hasConcept C2778375690 @default.
• W2168664391 hasConcept C2781209748 @default.
• W2168664391 hasConcept C31760486 @default.
• W2168664391 hasConcept C71924100 @default.
• W2168664391 hasConcept C90924648 @default.
• W2168664391 hasConceptScore W2168664391C126322002 @default.
• W2168664391 hasConceptScore W2168664391C141071460 @default.
• W2168664391 hasConceptScore W2168664391C197934379 @default.
• W2168664391 hasConceptScore W2168664391C2776256026 @default.
• W2168664391 hasConceptScore W2168664391C2776694085 @default.
• W2168664391 hasConceptScore W2168664391C2777063308 @default.
• W2168664391 hasConceptScore W2168664391C2778119113 @default.
• W2168664391 hasConceptScore W2168664391C2778239845 @default.
• W2168664391 hasConceptScore W2168664391C2778375690 @default.
• W2168664391 hasConceptScore W2168664391C2781209748 @default.
• W2168664391 hasConceptScore W2168664391C31760486 @default.
• W2168664391 hasConceptScore W2168664391C71924100 @default.
• W2168664391 hasConceptScore W2168664391C90924648 @default.
• W2168664391 hasIssue "13" @default.
• W2168664391 hasLocation W21686643911 @default.
• W2168664391 hasLocation W21686643912 @default.
• W2168664391 hasOpenAccess W2168664391 @default.
• W2168664391 hasPrimaryLocation W21686643911 @default.
• W2168664391 hasRelatedWork W1565978936 @default.
• W2168664391 hasRelatedWork W1826081227 @default.
• W2168664391 hasRelatedWork W1994125700 @default.
• W2168664391 hasRelatedWork W2045359153 @default.
• W2168664391 hasRelatedWork W2060932390 @default.
• W2168664391 hasRelatedWork W2075571760 @default.
• W2168664391 hasRelatedWork W2153372063 @default.
• W2168664391 hasRelatedWork W2386624876 @default.

• next